During the past two decades, soy isoflavones (commonly genistein, daidzein and equol) have gained significant
attention from the scientific community, primarily due to their beneficial effects in the treatment of ageing
symptoms in both genders1. Namely, some positive outcome was noticed in the soy isoflavone treatment of breast,
ovary and prostate cancer, and then osteoporosis, cardiovascular disease, diabetes, asthma, Kawasaki syndrome,